Navigation Links
AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS
Date:6/23/2009

VIENNA, Austria, June 23 /PRNewswire/ -- MIG Fonds and AFFiRiS AG are this year's winners of the 2009 Venture Capital & Private Equity Award competition, hosted by the industry magazine Boerse-Express and Junge Industrie. The award recognised the long-standing association between the German venture fund and the Austrian biotechnology company as well as a euro 430 million deal between AFFiRiS and GSK Biologicals.

Last Tuesday MIG Fonds and AFFiRiS AG were awarded first place in the Venture Capital and Private Equity (VC/PE) awards by the Austrian industry magazine Boerse-Express.com and their co-sponsors Junge Industrie. The winners were chosen following a special selection process that combines the perspectives of the magazine's readers and selected experts, who evaluate corporate success stories from different perspectives. This year, an investment relationship that has been fruitful for both venture partners was recognised and the importance of VC financing for the start-up period of innovative businesses was thereby recognised.

Dr. Walter Schmidt, co-founder and CEO of AFFiRiS AG, commented that the VC/PE awards "have a very special significance for the capital investment market in Austria because they demonstrate the vital function of VC in the development of promising high-tech businesses. In our case, three years ago MIG Fonds started to invest a total of euro 11.5 million. Without this capital, our licensing deal with GSK Biologicals three years later would not have been possible. This deal is for up to euro 430 million in upfront and milestone payments for our Alzheimer's vaccines. MIG Fonds' decision to invest has therefore already been beneficial for everyone involved."

Based on the MIG Fonds investment, AFFiRiS AG was able to develop its AFFITOME(R) technology, which delivers innovative vaccines with very specific properties. The firm has already announced the development of c
'/>"/>

SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
2. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
3. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
4. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
5. The next generation: nanomagnets could replace semiconductors
6. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
7. First European IGRT School Takes Place for Radiotherapy Practitioners in UK
8. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
9. Campbell Alliance Named Best Place to Work by Triangle Business Journal
10. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or ... any jurisdiction where to do so would constitute a violation ... plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... it has held a meeting with representatives of AbbVie. ... prior agreement or approval of AbbVie. A further ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market ... $140 billion in 2013. This is estimated to grow ... annual growth rate (CAGR) of 28.6%. , New digital ... exciting possibilities within the broader PCR field. The opportunities ...
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
(Date:7/11/2014)... Scottsdale, AZ (PRWEB) July 11, 2014 ... medicine device company specializing in the soft tissue ... SureLock All-Suture Anchor System for surgeries involving the ... predictable fixation through a novel, inserter-controlled deployment method. ... lead to partial deployment, anchor pull-out, or anchor ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... and focus on mission, CHICAGO, Feb. 25 ... Foundation as its expected provider of,clinical services for ... research center to be built in the DuPage ... The announcement came as Northern Illinois University ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... for solid tumors and,hematological malignancies, today announced that ... year-end financial results on Monday, Mar. 3,2008. SuperGen ... and provide financial guidance for fiscal year-end 2008., ...
... (Nasdaq: IDIX ), a biopharmaceutical company engaged,in the ... human viral,and other infectious diseases, announced today that three ... Meeting of the European,Association for the Study of the ... - 27, 2008. Full abstracts can now be viewed ...
Cached Biology Technology:NIU Seeks OK for New Proton Cancer Treatment and Research Center 2NIU Seeks OK for New Proton Cancer Treatment and Research Center 3SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 2Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) 3
(Date:7/11/2014)... many fires burning in eastern New South Wales, Australia ... , At 03:35 UTC on July 11 (12:35 p.m. ... passed over eastern New South Wales (NSW), the Moderate ... image of the region and spotted smoke (light brown) ... thermal bands, are outlined in red. , The New ...
(Date:7/11/2014)... USC Stem Cell scientists have set a "mouse TRAP" ... described by a recent study published in the ... line uses a technique called TRAP to extract cellular ... , Invented by scientists at the Rockefeller Institute for ... tag to the protein-making machinery, or ribosomes, of the ...
(Date:7/11/2014)... international team of researchers, including scientists from the Max ... a reported a major step in understanding photosynthesis, the ... maintains the oxygen in its atmosphere and which is ... earth. , The researchers report the first direct ... namely the step in which a specific protein complex, ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2
... Particle Whisperers , G. Volpe, S. Perrone, J. M. Rubi, ... As many parents know, it,s often easier to keep your ... A child who fidgets uncontrollably in a confining booster seat, ... chair. A team of physicists at the Universitat de Barcelona ...
... bubonic plague may be more virulent than their close relatives ... in the May issue of the journal Microbiology. The ... at body temperature. When there is no calcium available, it ... acid, said Professor Brubaker from the University of Chicago, USA. ...
... health organisations around the world. The worry is the potential ... develop the ability to infect humans easily. New drugs and ... needed. Now one of the tactics used by influenza virus ... laid bare by structural biologists at the European Molecular Biology ...
Cached Biology News:A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 2A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 3A gentle touch for better control, a quantum mechanical con, and milestone PRL papers 4Getting wise to the influenza virus' tricks 2
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... Rabbit polyclonal to Peroxiredoxin 1 ... peroxidase family, whose mammalian members have ... proliferation, differentiation, and apoptosis. Many isoforms ... to the amino acid sequence homology, ...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
Biology Products: